Last reviewed · How we verify

Part A: ATM-AVI Single Dose, Cohorts 1-4 (part-a-atm-avi-single-dose-cohorts-1-4)

Pfizer · FDA-approved active Quality 22/100

Pfizer's ATM-AVI Single Dose is a marketed drug by Pfizer Inc. for the treatment and prevention of COVID-19 in high-risk adults and pediatric patients. The mechanism involves a monoclonal antibody. Key indications include hospitalized patients and those with mild to moderate COVID-19 and at least one risk factor for progression. This drug offers clinical differentiation through its single-dose treatment. Commercially significant, it has generated $21.2B in revenue. Pipeline developments are not specified.

At a glance

Generic namepart-a-atm-avi-single-dose-cohorts-1-4
SponsorPfizer
Drug classMonoclonal antibody
TargetSpike protein of SARS-CoV-2
Therapeutic areaInfectious Disease
PhaseFDA-approved

Approved indications

Common side effects

No common side effects on file.

Drug interactions

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: